### Edgar Filing: FORMELA JEAN FRANCOIS - Form 4

#### FORMELA JEAN FRANCOIS

Form 4

October 24, 2012

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

**OMB APPROVAL** 

response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* FORMELA JEAN FRANCOIS

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

ARCA biopharma, Inc. [ABIO]

(First) (Middle) (Last)

3. Date of Earliest Transaction

X Director

X 10% Owner

C/O ATLAS VENTURE, 25 FIRST

10/22/2012

(Month/Day/Year)

Other (specify Officer (give title below)

6. Individual or Joint/Group Filing(Check

STREET, SUITE 303

4. If Amendment, Date Original (Street) Filed(Month/Day/Year)

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

CAMBRIDGE, MA 02141

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of 2. Transaction Date 2A. Deemed Security (Month/Day/Year) (Instr. 3)

Execution Date, if (Month/Day/Year)

4. Securities Acquired (A) 3. Transaction Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)

5. Amount of Securities Beneficially Owned Following Reported

7. Nature of Ownership Indirect Form: Direct (D) or Indirect

Beneficial Ownership (Instr. 4)

(A) or Code V (D) Amount Price

Transaction(s) (Instr. 4) (Instr. 3 and 4)

(I)

Common Stock

10/22/2012

Α 317.379  $1,579,542 \stackrel{(1)}{=} I$ 

See Foonote (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

### Edgar Filing: FORMELA JEAN FRANCOIS - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	e, if TransactionDerivative Code Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun Underlying Securiti (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amou Numl Share
Common Stock Warrants (right to buy)	\$ 0.3001	10/22/2012		A	238,034	10/25/2012(2)	10/25/2017	Common Stock	238,

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
•	Director	10% Owner	Officer	Other		
FORMELA JEAN FRANCOIS C/O ATLAS VENTURE 25 FIRST STREET, SUITE 303 CAMBRIDGE, MA 02141	X	X				

# **Signatures**

/s/ Frank Castellucci, Attorney-in-Fact

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Includes 1,262,163 shares of Common Stock held by Atlas Venture Fund VII, L.P. prior to the reported transaction. Atlas Venture

  Associates VII, L.P. or AVA VII, L.P. is the sole general partner of AV VII. Each Atlas VII and AVA VII LP disclaims beneficial ownership of such shares except to the extent of it's pecuniary interest therein. Dr. Formela is a Partner with Atlas Venture and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
- (2) The warrants are fully vested and exercisable upon issuance and have a contractual term of 5 years.
  - Includes warrants to purchase 75449 shares of common stock held by Atlas Venture Fund VII, L.P. prior to the reported transaction. Atlas Venture Associates VII, L.P. or AVA VII, L.P. is the sole general partner of AV VII. Each Atlas VII and AVA VII LP disclaims
- beneficial ownership of such shares except to the extent of it's pecuniary interest therein. Dr. Formela is a Partner with Atlas Venture and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2